Zymeworks Archives | Be Korea-savvy

Home / Posts tagged Zymeworks

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 status Late-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January [...]

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Strategy will combine internal innovation, licensing, and strategic acquisitions to drive sustainable value creation for shareholders Strategic initiative follows positive topline results from pivotal Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) and pasritamig advancing to registration studies by J&J Innovative Medicine (J&J) Eligible to receive up to $440.0 million in potential [...]

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal

Ziihera® plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysis Ziihera plus Tevimbra® (tislelizumab) and chemotherapy demonstrated clinically meaningful and statistically significant improvements in OS and PFS versus trastuzumab and [...]

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and non-small cell lung cancer. Data from the Phase 1 trial of ZW191 provide readthrough to Zymeworks’ broader ADC portfolio utilizing its novel bystander active topoisomerase-1 inhibitor payload, ZD06519. [...]

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

VANCOUVER, British Columbia, Oct. 09, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the appointment of Adam Schayowitz, Ph.D., MBA as Acting Chief Development Officer. In this role, [...]

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

VANCOUVER, British Columbia, April 21, 2025 (Korea Bizwire) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. [...]

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 26, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Needham 24th Annual Virtual [...]

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety profile New antibody-drug conjugate (ADC) candidate, ZW327, exhibits anti-tumor activity and a favorable pharmacokinetics profile in Ly6E-bearing cancers VANCOUVER, British Columbia, March 25, 2025 (Korea Bizwire) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse [...]

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, Feb. 25, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: TD Cowen 45th Annual [...]

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

VANCOUVER, British Columbia, Feb. 13, 2025 (Korea Bizwire) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its fourth quarter and full year 2024 financial results [...]